دورية أكاديمية
Safety of Everolimus by Treatment Duration in Patients With Advanced Renal Cell Cancer in an Expanded Access Program
| العنوان: | Safety of Everolimus by Treatment Duration in Patients With Advanced Renal Cell Cancer in an Expanded Access Program |
|---|---|
| المساهمون: | Alfonsus J.M. van den Eertwegh, Pierre Karakiewicz, Sevil Bavbek, Sun Young Rha, Sergio Bracarda, Amit Bahl, Yen-chuan Ou, Dennis Kim, Ashok Panneerselvam, Oezlem Anak, Viktor Gr체nwald, Rha, Sun Young |
| سنة النشر: | 2013 |
| مصطلحات موضوعية: | Aged, Anemia/chemically induced, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Carcinoma, Renal Cell/drug therapy, Renal Cell/secondary, Disease Progression, Dyspnea/chemically induced, Everolimus, Fatigue/chemically induced, Female, Humans, Hyperglycemia/chemically induced, Kidney Neoplasms/drug therapy, Kidney Neoplasms/pathology, Male, Middle Aged, Pneumonia/chemically induced, Sirolimus/adverse effects, Sirolimus/analogs & derivatives, Sirolimus/therapeutic use, Stomatitis/chemically induced, Time Factors, Treatment Outcome |
| الوصف: | OBJECTIVE: To retrospectively analyze the effects of treatment duration on outcomes of everolimus treatment of patients in the RAD001 Expanded-Access Clinical Trial in RCC (REACT) program. METHODS: Patients with metastatic renal cell carcinoma refractory to vascular endothelial growth factor receptor-tyrosine kinase inhibitor received everolimus (10 mg once daily), with dosing interruption or modifications allowed for toxicity. All serious and grade 3/4 adverse events and grade 1/2 adverse events leading to a change in drug administration were reported. Tumor response was evaluated using Response Evaluation Criteria In Solid Tumors. RESULTS: The study stratified 1367 evaluable patients into treatment duration groups of <3 months, �돟3 and <6 months, �돟6 months and <1 year, and �돟1 year. Pneumonia, noninfectious pneumonitis, and hyperglycemia occurred more frequently in patients receiving everolimus for �돟1 year but did not result in treatment discontinuations. First occurrence of adverse events presented early in the treatment course for most patients. Treatment duration of �돟6 months was associated with improved disease control rates. CONCLUSION: Everolimus is well tolerated in patients with metastatic renal cell carcinoma for treatment durations�돟1 year and not associated with cumulative toxicity. ; open |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| تدمد: | 0090-4295 1527-9995 |
| العلاقة: | UROLOGY; J02775; OAK-2013-00465; https://ir.ymlib.yonsei.ac.kr/handle/22282913/86583Test; http://www.sciencedirect.com/science/article/pii/S0090429512011107Test; T201300724; UROLOGY, Vol.81(1) : 143-149, 2013 |
| DOI: | 10.1016/j.urology.2012.09.019 |
| الإتاحة: | https://doi.org/10.1016/j.urology.2012.09.019Test https://ir.ymlib.yonsei.ac.kr/handle/22282913/86583Test http://www.sciencedirect.com/science/article/pii/S0090429512011107Test |
| حقوق: | CC BY-NC-ND 2.0 KR ; https://creativecommons.org/licenses/by-nc-nd/2.0/krTest/ ; not free |
| رقم الانضمام: | edsbas.8789153F |
| قاعدة البيانات: | BASE |
| تدمد: | 00904295 15279995 |
|---|---|
| DOI: | 10.1016/j.urology.2012.09.019 |